Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center, Taipei 112, Taiwan.
Int J Mol Sci. 2019 Jan 14;20(2):306. doi: 10.3390/ijms20020306.
The G-protein coupled estrogen receptor (GPER), an alternate estrogen receptor (ER) with a structure distinct from the two canonical ERs, being ERα, and ERβ, is expressed in 50% to 60% of breast cancer tissues and has been presumed to be associated with the development of tamoxifen resistance in ERα positive breast cancer. On the other hand, triple-negative breast cancer (TNBC) constitutes 15% to 20% of breast cancers and frequently displays a more aggressive behavior. GPER is prevalent and involved in TNBC and can be a therapeutic target. However, contradictory results exist regarding the function of GPER in breast cancer, proliferative or pro-apoptotic. A better understanding of the GPER, its role in breast cancer, and the interactions with the ER and epidermal growth factor receptor will be beneficial for the disease management and prevention in the future.
G 蛋白偶联雌激素受体（GPER）是一种与两种经典雌激素受体（ER）即 ERα和 ERβ结构不同的雌激素受体，在 50%至 60%的乳腺癌组织中表达，并且被认为与 ERα阳性乳腺癌中他莫昔芬耐药的发展有关。另一方面，三阴性乳腺癌（TNBC）占乳腺癌的 15%至 20%，并且经常表现出更具侵袭性的行为。GPER 在 TNBC 中普遍存在且与之相关，可以作为治疗靶点。然而，关于 GPER 在乳腺癌中的作用，即增殖或促凋亡，存在矛盾的结果。更好地了解 GPER、它在乳腺癌中的作用以及与 ER 和表皮生长因子受体的相互作用，将有助于未来对该疾病进行管理和预防。
